Dr. Michael Postow on the Toxicities of Melanoma-Treating Targeted Therapy Combinations
Postow cites the combination of vemurafenib and ipilimumab as one that produced a high rate of liver inflammation and skin rash in patients, which was then deemed not to be given to patients outside of clinical trials.
Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering, discusses the need for further investigation into targeted agent combinations due to high rates of toxicities in patients with melanoma. Postow cites the combination of vemurafenib and ipilimumab as one that produced a high rate of liver inflammation and skin rash in patients, which was then deemed not to be given to patients outside of clinical trials.
Recent Videos
Related Content
